Α. Kotsakis

500 total citations
23 papers, 338 citations indexed

About

Α. Kotsakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Α. Kotsakis has authored 23 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Α. Kotsakis's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Α. Kotsakis is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Α. Kotsakis collaborates with scholars based in Greece, United States and Australia. Α. Kotsakis's co-authors include Vassilis Georgoulias, Athanassios Argiris, Despoina Aggouraki, Paul Cordopatis, Sofia Agelaki, Dimitris Mavroudis, Athanasios Galanis, Kostas Kosmatopoulos, Dora Hatzidaki and L. Vamvakas and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Α. Kotsakis

22 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Α. Kotsakis Greece	11	223	147	132	65	53	23	338
Francesca Sparano Italy	9	219 1.0×	103 0.7×	113 0.9×	78 1.2×	65 1.2×	19	369
Akihisa Kiyota Japan	10	242 1.1×	73 0.5×	161 1.2×	15 0.2×	48 0.9×	11	357
Anna‐Kaisa Eerola Finland	6	264 1.2×	66 0.4×	182 1.4×	125 1.9×	60 1.1×	7	407
Grégoire Marret France	8	119 0.5×	74 0.5×	96 0.7×	31 0.5×	48 0.9×	24	231
Arsène‐Bienvenu Loembé United Kingdom	9	196 0.9×	100 0.7×	168 1.3×	42 0.6×	33 0.6×	15	377
M. D’Arcangelo Italy	12	200 0.9×	196 1.3×	119 0.9×	41 0.6×	79 1.5×	31	360
Shinya Ohara Japan	12	159 0.7×	152 1.0×	115 0.9×	32 0.5×	43 0.8×	29	376
Michael Shafique United States	9	287 1.3×	120 0.8×	167 1.3×	86 1.3×	37 0.7×	35	412
He-San Luo China	12	158 0.7×	151 1.0×	194 1.5×	27 0.4×	115 2.2×	24	450
Frank Ziemann Germany	8	113 0.5×	57 0.4×	121 0.9×	23 0.4×	58 1.1×	10	259

Countries citing papers authored by Α. Kotsakis

Since Specialization

Citations

This map shows the geographic impact of Α. Kotsakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Α. Kotsakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Α. Kotsakis more than expected).

Fields of papers citing papers by Α. Kotsakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Α. Kotsakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Α. Kotsakis. The network helps show where Α. Kotsakis may publish in the future.

Co-authorship network of co-authors of Α. Kotsakis

This figure shows the co-authorship network connecting the top 25 collaborators of Α. Kotsakis. A scholar is included among the top collaborators of Α. Kotsakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Α. Kotsakis. Α. Kotsakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Markou, Athina, Ioannis Vamvakaris, Κonstantinos Potaris, et al.. (2022). DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. Clinical Epigenetics. 14(1). 61–61. 29 indexed citations

Kotoula, Vassiliki, Kalliopi Tsakiri, Georgia-Angeliki Koliou, et al.. (2018). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. Clinical Breast Cancer. 19(2). 113–125.e4. 8 indexed citations

Vetsika, Eleni‐Kyriaki, et al.. (2016). Predictive/prognostic value of circulating regulatory T cell subset in untreated non-small lung cancer patients. Annals of Oncology. 27. vi25–vi25. 1 indexed citations

Matikas, Alexios, Vassilis Georgoulias, & Α. Kotsakis. (2016). The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. Expert Review of Respiratory Medicine. 10(11). 1229–1241. 10 indexed citations

Kotsakis, Α., Sofia Agelaki, Athina Agelidou, et al.. (2015). Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology. 75(4). 821–827. 18 indexed citations

Georgoulias, Vasilis, Stella Apostolaki, V. Bozionelou, et al.. (2014). Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 74(6). 1217–1225. 7 indexed citations

Ramalingam, Suresh S., Α. Kotsakis, Ahmad A. Tarhini, et al.. (2013). A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 81(3). 416–421. 17 indexed citations

Mountzios, Giannis, Christos Emmanouilidis, N. Vardakis, et al.. (2012). Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer. 77(1). 146–150. 33 indexed citations

Argiris, Athanassios, Ryan P. Smith, Α. Kotsakis, et al.. (2011). Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology. 22(11). 2482–2488. 12 indexed citations

10.

Kotsakis, Α., Suresh S. Ramalingam, Ahmad A. Tarhini, et al.. (2011). Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7019–7019. 7 indexed citations

11.

Vamvakas, L., Sofia Agelaki, Athanasios Karampeazis, et al.. (2010). Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.. Journal of Clinical Oncology. 28(15_suppl). 7519–7519. 35 indexed citations

12.

Ferris, Robert L., Α. Kotsakis, Dwight E. Heron, et al.. (2010). A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 28(15_suppl). TPS262–TPS262. 4 indexed citations

13.

Kotsakis, Α., William E. Gooding, & Athanassios Argiris. (2010). Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck.. Journal of Clinical Oncology. 28(15_suppl). TPS271–TPS271. 2 indexed citations

14.

Kotsakis, Α., Ahmad A. Tarhini, Daniel P. Petro, et al.. (2009). Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC). Journal of Clinical Oncology. 27(15_suppl). 8107–8107. 11 indexed citations

15.

Gibson, Michael K., M.S. Kies, Sohyoung Kim, et al.. (2009). Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. Journal of Clinical Oncology. 27(15_suppl). 6049–6049. 12 indexed citations

16.

Kotsakis, Α., Despoina Aggouraki, Athanasios Galanis, et al.. (2007). Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide. Journal of Clinical Oncology. 25(19). 2727–2734. 85 indexed citations

17.

Kosmatopoulos, K., et al.. (2006). Clinical efficacy and immunogenicity of the optimized cryptic peptide TERT_572Y vaccine (Vx-001) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17069–17069. 2 indexed citations

18.

Kakolyris, S., Charalambos Kouroussis, John Souglakos, et al.. (1998). Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 21. S32–S32. 2 indexed citations

19.

Androulakis, N., S. Kakolyris, E. Papadakis, et al.. (1998). Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxelbased chemotherapy: a multicenter phase II study. Lung Cancer. 21. S36–S36. 3 indexed citations

20.

Papadakis, E., C. Kourousis, Stylianos Kakolyris, et al.. (1997). 163 Second line treatment of advanced non-small-cell lung cancer after cisplatin-based chemotherapy with paclitaxel and gemcitabine. Lung Cancer. 18. 44–44. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact